

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Frants et al.

Serial No.: 10/619,898

Filed: July 14, 2003

For: GENE RELATED TO MIGRAINE IN

MAN

Confirmation No.: 7453

Examiner: S. Chen

Group Art Unit: 1632

Attorney Docket No.: 2183-6260.1US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV669814831US

Date of Deposit with USPS: September 6, 2006

Person making Deposit: Brett Hooke

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Pursuant to 37 C.F.R. § 1.98(d), a copy of any patent, publication or other information listed in the Information Disclosure Statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is

Serial No.: 10/619,898

properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. § 120.

Accordingly, no copy of information marked with a pound sign (#) is enclosed because it was previously cited or submitted to the patent office in a prior application which is properly identified, and is relied upon for an earlier filing date. The references are as follows:

U.S. Patent Documents

U.S. Patent No.	Publication Date	<u>Patentee</u>
US- 6,825,332 B1	11-30-2004	Frants et al.

Foreign Patent Documents

Document No.	Publication Date	<u>Patentee</u>
#WO 95 04822 A	02-1995	

Other Documents

#ELLIS et al., GenBank Seq. No. AAQ84660, 1995, 5-8.

#ELLIS et al., GenBank Seq. No. AAQ84660, 1995, 5-9.

#SKOLNICK et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, 2000, TIBETECH, vol. 18:34-39.

#KAYE et al., A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, 1990, Proc. Natl. Acad. Sci., vol 87:6922-26.

#RUDINGER, Characteristics of the amino acids as components of a peptide hormone sequence, 1976, Peptide Hormones: 1-7.

#ELLIS et al., AC Q84659, Feb. 16, 1995, Gene seq. 36.

#OPOFF, R.A., AC Z80116, Nov. 1, 1996, Gene Embl.

#OPHOFF, R.A., et al., (Oct 24-28, 1995) Am J. of Human Genetics 57 (4 Suppl.).

#SOLDATOV, N., (1994) Genomics 22:77-87.

#LEWIN, B., (1994) "Genes V" Oxford U. Press.

Serial No.: 10/619,898

#HULLIN, R., et al., (1992) The Embo Journal 11:3:885-90.

#PEREZ-REYES, et al., (Jan 25, 1992) J of Biol Chem 267:3:1792-977.

#BROWNE, et al., (1994) Nat. Genet. 8:136-140.

#DIRIONG, et al., (1995) Genomics, 30:605-609.

#FLETCHER, et al., (1996) Cell 87:607-17.

#HOVATTA et al., (1994) Genomics 23:707-09.

#JOUTEL, et al., (1993) Nature Genet. 5:40-45.

#JOUTEL et al., (1994) Am. J. Hum. Genet. 55:1166-1172.

#JOUTEL et al., (1994) Rev. Neurol. 150:340-45.

#LARA, et al., (1995) Rev. Neurol. 23 supp 2:S179-184.

#MAY, et al., (1995) Hum. Genet. 96:604-08.

#VAHEDI et al., (1995) Ann. Neurol. 37:289-293.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/269,446

Filed: Sep. 26, 1997

For: GENE RELATED TO MIGRAINE IN MAN, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

This Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

espectfully submitted,

The PTO did not receive the following listed Item(s) The Fee enclosed.

Allen C. Turner Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: September 6, 2006

ACT/bv

Enclosures: Form PTO/SB/08Document in ProLaw

Approved for use through 10/31/2002. OMB 0651-0031

S. Chen

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 APTO THE PAPER STATEMENT BY APPLICANT

Application Number 10/619,898

Filing Date July 14, 2003

First Named Inventor Frants et al.

Group Art Unit 1632

(use as many sheets as necessary)

Sheet 1 of 3 Attorney Docket Number 2183-6260.1US

U.S. PATENT DOCUMENTS Document Number						
Examiner Initials *	Cite No.1	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US- 6,825,332 B1	11-30-2004	Frants et al.		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		1		
•		US-				
		US-				
		US-				
		US-				
	[US-				
		US-				
		US-				
		US-				
		US-				
		US-				

Examiner Name

FOREIGN PATENT DOCUMENTS						
Examiner Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
		#WO 95 04822 A	02-1995			
			-	<u> </u>	 	
			+			
			 			

Examiner Signature	Date Considered	
	 	L

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

SEP 0 6 2006

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/619,898 INFORMATION DISCLOSURE Filing Date July 14, 2003 STATEMENT BY APPLICANT First Named Inventor Frants et al. Group Art Unit 1632 (use as many sheets as necessary) S. Chen **Examiner Name** Attorney Docket Number 2183-6260 1US

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		#ELLIS et al., GenBank Seq. No. AAQ84660, 1995, 5-8.	
		#ELLIS et al., GenBank Seq. No. AAQ84660, 1995, 5-9.	
		#SKOLNICK et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, 2000, TIBETECH, vol. 18:34-39.	
		#KAYE et al., A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, 1990, Proc. Natl. Acad. Sci., vol 87:6922-26.	,
		#RUDINGER, Characteristics of the amino acids as components of a peptide hormone sequence, 1976, Peptide Hormones: 1-7.	
		#ELLIS et al., AC Q84659, Feb. 16, 1995, Gene seq. 36.	
		#OPOFF, R.A., AC Z80116, Nov. 1, 1996, Gene Embl.	
-		#OPHOFF, R.A., et al., (Oct 24-28, 1995) Am J. of Human Genetics 57 (4 Suppl.).	
		#SOLDATOV, N., (1994) Genomics 22:77-87.	
		#LEWIN, B., (1994) "Genes V" Oxford U. Press.	
		#HULLIN, R., et al., (1992) The Embo Journal 11:3:885-90.	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0651-0031

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known Application Number 10/619,898 Filing Date July 14, 2003 First Named Inventor Frants et al. Group Art Unit 1632 Examiner Name S. Chen Attorney Docket Number 2183-6260 HUS

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		#PEREZ-REYES, et al., (Jan 25, 1992) J of Biol Chem 267:3:1792-977.		
		#BROWNE, et al., (1994) Nat. Genet. 8:136-140.		
		#DIRIONG, et al., (1995) Genomics, 30:605-609.		
		#FLETCHER, et al., (1996) Cell 87:607-17.		
		#HOVATTA et al., (1994) Genomics 23:707-09.		
		#JOUTEL, et al., (1993) Nature Genet. 5:40-45.		
		#JOUTEL et al., (1994) Am. J. Hum. Genet. 55:1166-1172.		
		#JOUTEL et al., (1994) Rev. Neurol. 150:340-45.		
		#LARA, et al., (1995) Rev. Neurol. 23 supp 2:S179-184.		
		#MAY, et al., (1995) Hum. Genet. 96:604-08.		
		#VAHEDI et al., (1995) Ann. Neurol. 37:289-293.		

Examiner	Date	
Signature	Considered	

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/269,446

Filed: Sep. 26, 1997

For: GENE RELATED TO MIGRAINE IN MAN, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.